YB-1: The key to personalised prostate cancer management?

Mark Bates; Anna Boland; Niamh McDermott; Laure Marignol

doi:10.1016/j.canlet.2020.07.006

YB-1: The key to personalised prostate cancer management?

Cancer Lett. 2020 Oct 10:490:66-75. doi: 10.1016/j.canlet.2020.07.006. Epub 2020 Jul 16.

Authors

Mark Bates¹, Anna Boland¹, Niamh McDermott¹, Laure Marignol²

Affiliations

¹ Translational Radiobiology and Molecular Oncology Group, Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin 2, Ireland.
² Translational Radiobiology and Molecular Oncology Group, Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin 2, Ireland. Electronic address: marignl@tcd.ie.

PMID: 32681926
DOI: 10.1016/j.canlet.2020.07.006

Abstract

Y-box-binding protein 1 (YB-1) is a DNA/RNA binding protein increasingly implicated in the regulation of cancer cell biology. Normally located in the cytoplasm, nuclear localisation in prostate cancer is associated with more aggressive, potentially treatment-resistant disease. This is attributed to the ability of YB-1 to act as a transcription factor for various target genes associated with androgen receptor signalling, survival, DNA repair, proliferation, invasion, differentiation, angiogenesis and hypoxia. This review aims to examine the clinical potential of YB-1 in the detection and therapeutic management of prostate cancer.

Keywords: Prognostic biomarkers; Prostate cancer; Radiation therapy; Treatment resistance; Y-box-binding protein 1.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Biomarkers, Tumor*
Humans
Male
Precision Medicine
Prostatic Neoplasms, Castration-Resistant / genetics
Prostatic Neoplasms, Castration-Resistant / metabolism*
Prostatic Neoplasms, Castration-Resistant / pathology*
Y-Box-Binding Protein 1*

Substances

Biomarkers, Tumor
Y-Box-Binding Protein 1
YBX1 protein, human